Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKLIEF vs AKRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
FDA-approved for the topical treatment of acne vulgaris in patients 9 years of age and older
Allergic rhinitis,Nasal congestion
Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.
Adults: 100 mg orally twice daily.
Terminal elimination half-life: ~29 hours after topical application; supports once-daily dosing.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
Trifarotene is metabolized primarily via CYP2D6 and to a lesser extent via CYP3A4. It undergoes extensive first-pass metabolism with low systemic exposure after topical application.
Not available; components may be metabolized via hepatic CYP enzymes.
Fecal: ~70% as unchanged drug; Renal: <1% as metabolites.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
>99% bound to plasma proteins (primarily albumin and lipoproteins).
99.5% (primarily to albumin; also to α1-acid glycoprotein).
Not determined for topical route; systemic absorption minimal with Vd not clinically relevant.
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
Topical: ~1% systemic absorption; oral: not applicable.
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
No dose adjustment required in renal impairment. Not studied in severe renal impairment.
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
No dose adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C).
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
Approved for acne vulgaris in patients aged 12 years and older: apply a thin layer to affected areas once daily in the evening.
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
No specific dose adjustment required; clinical studies did not include sufficient geriatric patients to determine differential response.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
None.
None
Local skin reactions (erythema, scaling, dryness, stinging/burning) may occur; reduce frequency or discontinue if severe.,Avoid excessive exposure to sunlight or UV light; use sunscreens and protective clothing.,Avoid contact with eyes, mouth, angles of the nose, and mucous membranes.,Pregnancy: Limited data; no known risk of major malformations based on animal studies, but use only if clearly needed.
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Hypersensitivity to trifarotene or any component of the formulation
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
No significant food interactions reported. Avoid excessive alcohol consumption as it may exacerbate skin dryness and irritation. No specific dietary restrictions.
No known food interactions with topical naftifine. No dietary restrictions required.
Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters: Limited data; avoid unless benefit outweighs risk.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
No data on excretion in human milk; M/P ratio unknown. Caution advised due to potential for serious adverse reactions in nursing infants.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
No specific dose adjustments recommended; pharmacokinetic changes in pregnancy unknown. Use lowest effective dose if necessary.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
AKLIEF (trifarotene) is a fourth-generation retinoid selective for RAR-γ receptors, minimizing irritation compared to tretinoin. Use pea-sized amount for entire face; avoid excessive application. Initiate every other night to improve tolerability. Concomitant use of benzoyl peroxide or salicylic acid may increase dryness; advise non-comedogenic moisturizers. Contraindicated in pregnancy (Category X); rule out pregnancy before starting.
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
Apply a thin layer once daily at night to clean, dry skin.,Avoid sun exposure and use broad-spectrum SPF 30+ sunscreen daily.,May cause initial redness, peeling, and dryness; use moisturizer.,Do not use if pregnant or planning pregnancy; use effective contraception.,Do not apply to cuts, abrasions, or eczematous skin.,Avoid waxing or laser hair removal during treatment.,Therapeutic effect may take 8-12 weeks.,Keep out of reach of children and away from eyes, mouth, and mucous membranes.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKLIEF vs AKRINOL, answered by our medical review team.
AKLIEF is a Topical Retinoid that works by AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.. AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKLIEF and AKRINOL depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKLIEF is: Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.. The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKLIEF and AKRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKLIEF is classified as Category C. Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters:. AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.